Knibbe Catherijne A J, Zuideveld Klaas P, Aarts Leon P H J, Kuks Paul F M, Danhof Meindert
Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, the Netherlands.
Br J Clin Pharmacol. 2005 Jun;59(6):705-11. doi: 10.1111/j.1365-2125.2005.02239.x.
Allometric equations have proven useful for the extrapolation of animal data to determine pharmacokinetic parameters in man. It has been proposed that these equations are also applicable over the human size range including the paediatric population. The aim of this work was to study the relationship between various pharmacokinetic parameters for propofol and body weight using data from rats, children and adults. Furthermore, the utility of allometric scaling is evaluated by the prediction of propofol concentrations in humans based on data obtained in the rat.
The relationship between the pharmacokinetic parameters of propofol obtained in rats, children and adults was analyzed by plotting the logarithmically transformed parameters against the corresponding logarithmically transformed body weights. In addition, based on allometric equations, pharmacokinetic parameters obtained in rats were scaled to humans. These parameters were used to simulate propofol concentrations in long-term sedated critically ill patients using NONMEM. Simulated concentrations were then compared with actually observed concentrations in humans.
The relationship between pharmacokinetic parameters of propofol from rats, children and adults was in good agreement with those from the literature on allometric modelling. For clearance, intercompartmental clearance, central volume of distribution and peripheral volume of distribution, the power parameters were 0.78, 0.73, 0.98 and 1.1, respectively, and r2 values for the linear correlations were 0.990, 0.983, 0.977 and 0.994, respectively. On the basis of data obtained after a single bolus injection in the rat, adequate predictions of propofol concentrations in critically ill patients can be made using allometric equations, despite the long-term nature of the use of the drug, the large number of infusion changes per day and/or differences in state of health and age.
For propofol, allometric scaling has proved to be valuable for cross species extrapolation. Furthermore, the use of the allometric equation between adults and children seems to be an adequate tool for the development of rational dosing schemes for children of varying body weights, and requires further study.
异速生长方程已被证明可用于外推动物数据以确定人体药代动力学参数。有人提出这些方程也适用于包括儿科人群在内的人类体型范围。本研究的目的是利用大鼠、儿童和成人的数据,研究丙泊酚的各种药代动力学参数与体重之间的关系。此外,通过基于大鼠获得的数据预测人体丙泊酚浓度来评估异速生长标度的效用。
通过将对数转换后的参数与相应的对数转换后的体重作图,分析大鼠、儿童和成人中获得的丙泊酚药代动力学参数之间的关系。此外,基于异速生长方程,将大鼠中获得的药代动力学参数按比例换算到人体。这些参数用于使用NONMEM模拟长期镇静的重症患者中的丙泊酚浓度。然后将模拟浓度与人体中实际观察到的浓度进行比较。
大鼠、儿童和成人的丙泊酚药代动力学参数之间的关系与异速生长模型文献中的关系高度一致。对于清除率、隔室间清除率、中央分布容积和外周分布容积,幂参数分别为0.78、0.73、0.98和1.1,线性相关性的r2值分别为0.990、0.983、0.977和0.994。基于大鼠单次推注后获得的数据,尽管药物使用具有长期性质、每天输液变化次数多和/或健康状况和年龄存在差异,但使用异速生长方程可以对重症患者的丙泊酚浓度做出充分预测。
对于丙泊酚,异速生长标度已被证明对跨物种外推很有价值。此外,成人与儿童之间的异速生长方程的使用似乎是为不同体重儿童制定合理给药方案的合适工具,需要进一步研究。